| Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer S Muenst, AR Schaerli, F Gao, S Däster, E Trella, RA Droeser, MG Muraro, ... Breast cancer research and treatment 146, 15-24, 2014 | 585 | 2014 |
| Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings DL Musselman, AH Miller, MR Porter, A Manatunga, F Gao, S Penna, ... American Journal of Psychiatry 158 (8), 1252-1257, 2001 | 557 | 2001 |
| Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey D Morgensztern, SH Ng, F Gao, R Govindan Journal of thoracic oncology 5 (1), 29-33, 2010 | 552 | 2010 |
| The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer S Muenst, SD Soysal, F Gao, EC Obermann, D Oertli, WE Gillanders Breast cancer research and treatment 139, 667-676, 2013 | 356 | 2013 |
| Lower-dose vs high-dose oral estradiol therapy of hormone receptor–positive, aromatase inhibitor–resistant advanced breast cancer: A phase 2 randomized study MJ Ellis, F Gao, F Dehdashti, DB Jeffe, PK Marcom, LA Carey, MN Dickler, ... Jama 302 (7), 774-780, 2009 | 314 | 2009 |
| An “off-the-shelf” fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies ML Cooper, J Choi, K Staser, JK Ritchey, JM Devenport, K Eckardt, ... Leukemia 32 (9), 1970-1983, 2018 | 263 | 2018 |
| NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast CancerNeoadjuvant Palbo … CX Ma, F Gao, J Luo, DW Northfelt, M Goetz, A Forero, J Hoog, ... Clinical Cancer Research 23 (15), 4055-4065, 2017 | 255 | 2017 |
| Prospective study of [18F] fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma AS Kibel, F Dehdashti, MD Katz, AP Klim, RL Grubb, PA Humphrey, ... Journal of Clinical Oncology 27 (26), 4314, 2009 | 252 | 2009 |
| Utility of parametrectomy for early stage cervical cancer treated with radical hysterectomy JD Wright, PW Grigsby, R Brooks, MA Powell, RK Gibb, F Gao, JS Rader, ... Cancer 110 (6), 1281-1286, 2007 | 223 | 2007 |
| Preoperative lymph node staging of early‐stage cervical carcinoma by [18F]‐fluoro‐2‐deoxy‐D‐glucose–positron emission tomography JD Wright, F Dehdashti, TJ Herzog, DG Mutch, PC Huettner, JS Rader, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2005 | 218 | 2005 |
| Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of the endometrioid type I Zighelboim, PJ Goodfellow, F Gao, RK Gibb, MA Powell, JS Rader, ... Journal of Clinical Oncology 25 (15), 2042-2048, 2007 | 217 | 2007 |
| Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer CG Sanchez, CX Ma, RJ Crowder, T Guintoli, C Phommaly, F Gao, L Lin, ... Breast Cancer Research 13, 1-17, 2011 | 216 | 2011 |
| Distinctive characteristics of non-small cell lung cancer (NSCLC) in the young: a surveillance, epidemiology, and end results (SEER) analysis J Subramanian, D Morgensztern, B Goodgame, MQ Baggstrom, F Gao, ... Journal of Thoracic Oncology 5 (1), 23-28, 2010 | 205 | 2010 |
| Patient and tumor characteristics associated with increased mortality in young women (≤ 40 years) with breast cancer A Bharat, RL Aft, F Gao, JA Margenthaler Journal of surgical oncology 100 (3), 248-251, 2009 | 196 | 2009 |
| FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features SA Byron, M Gartside, MA Powell, CL Wellens, F Gao, DG Mutch, ... PloS one 7 (2), e30801, 2012 | 190 | 2012 |
| Delaying treatment of ocular hypertension: the ocular hypertension treatment study MA Kass, MO Gordon, F Gao, DK Heuer, EJ Higginbotham, CA Johnson, ... Archives of ophthalmology 128 (3), 276, 2010 | 190 | 2010 |
| Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast CancerNeratinib for HER2-Mutated, Nonamplified Breast Cancer CX Ma, R Bose, F Gao, RA Freedman, ML Telli, G Kimmick, E Winer, ... Clinical Cancer Research 23 (19), 5687-5695, 2017 | 173 | 2017 |
| A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing PM Fracasso, H Burris III, MA Arquette, R Govindan, F Gao, LP Wright, ... Clinical Cancer Research 13 (3), 986-993, 2007 | 171 | 2007 |
| Targeting CD123 in acute myeloid leukemia using a T-cell–directed dual-affinity retargeting platform M Al-Hussaini, MP Rettig, JK Ritchey, D Karpova, GL Uy, LG Eissenberg, ... Blood, The Journal of the American Society of Hematology 127 (1), 122-131, 2016 | 169 | 2016 |
| Combined microsatellite instability, MLH1 methylation analysis, and immunohistochemistry for Lynch syndrome screening in endometrial cancers from GOG210: an NRG Oncology and … PJ Goodfellow, CC Billingsley, HA Lankes, S Ali, DE Cohn, RJ Broaddus, ... Journal of Clinical Oncology 33 (36), 4301, 2015 | 169 | 2015 |
